{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T04:27:49Z","timestamp":1741753669493,"version":"3.38.0"},"reference-count":24,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"},{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Womens Health (Lond Engl)"],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:p> Bisphosphonates are the current mainstay of the management of osteoporosis worldwide. Oral daily and weekly formulations have been linked to poor adherence, yielding a decrease in antifracture efficacy, in real-life settings. Development of new bisphosphonates, with increased antiosteoclastic potency and affinity for bone matrix allowed intravenous administration and intervals between dosingsto be higher than weekly. Ibandronate and zoledronic acid have been investigated in established osteoporosis. Quarterly injections of ibandronate (3 mg) have been shown to be at least as effective in increasing bone mineral density and reducing bone turnover markers as the oral ibandronate regimen, which has proven antifracture efficacy. A once-yearly infusion of zoledronic acid (5 mg) during a 3-year period significantly reduced the risk of vertebral, hip and other fractures. Intravenous administration of bisphosphonates can now be considered as an important component of the management of postmenopausal osteoporosis. <\/jats:p>","DOI":"10.2217\/17455057.3.6.719","type":"journal-article","created":{"date-parts":[[2010,2,3]],"date-time":"2010-02-03T09:10:48Z","timestamp":1265188248000},"page":"719-723","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Injectable Bisphosphonates for the Treatment of Osteoporosis"],"prefix":"10.1177","volume":"3","author":[{"given":"Jean-Yves","family":"Reginster","sequence":"first","affiliation":[{"name":"University of Li\u00e8ge, Bone and Cartilage Metabolism Research Unit, CHU Centre-Ville, Policliniques L. BRULL, Quai Godefroid Kurth 45 (9\u00e8me \u00e9tage), 4020 Liege, Belgium, Tel.: +32 4270 3257; Fax: +32 4270 3253;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nansa","family":"Burlet","sequence":"additional","affiliation":[{"name":"International Osteoporosis Foundation, Nyon, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Close","sequence":"additional","affiliation":[{"name":"University of Li\u00e8ge, Department of Physical Medicine and Rehabilitation. CHU Sart Tilman, Liege, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Bruyere","sequence":"additional","affiliation":[{"name":"University of Li\u00e8ge, Bone and Cartilage Metabolism Research Unit, CHU Centre-Ville, Policliniques L. BRULL, Quai Godefroid Kurth 45 (9\u00e8me \u00e9tage), 4020 Liege, Belgium, Tel.: +32 4270 3257; Fax: +32 4270 3253;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2007,11,1]]},"reference":[{"unstructured":"Papers of special note have been highlighted as either of interest (\u2022) or of considerable interest (\u2022\u2022) to readers.","key":"bibr0101-17455057.3.6.719"},{"doi-asserted-by":"publisher","key":"bibr1-17455057.3.6.719","DOI":"10.1007\/s00198-004-1812-1"},{"doi-asserted-by":"publisher","key":"bibr2-17455057.3.6.719","DOI":"10.1016\/j.bone.2006.01.150"},{"doi-asserted-by":"publisher","key":"bibr3-17455057.3.6.719","DOI":"10.1056\/NEJM199610033351403"},{"doi-asserted-by":"publisher","key":"bibr4-17455057.3.6.719","DOI":"10.2217\/17460816.1.1.37"},{"doi-asserted-by":"publisher","key":"bibr5-17455057.3.6.719","DOI":"10.1016\/j.bone.2005.11.013"},{"doi-asserted-by":"publisher","key":"bibr6-17455057.3.6.719","DOI":"10.1016\/S0149-2918(01)80109-0"},{"doi-asserted-by":"publisher","key":"bibr7-17455057.3.6.719","DOI":"10.1016\/j.clinthera.2006.01.002"},{"doi-asserted-by":"publisher","key":"bibr8-17455057.3.6.719","DOI":"10.1007\/BF01623227"},{"doi-asserted-by":"publisher","key":"bibr9-17455057.3.6.719","DOI":"10.1016\/0378-5122(96)01118-8"},{"doi-asserted-by":"publisher","key":"bibr10-17455057.3.6.719","DOI":"10.1007\/s00198-006-0169-z"},{"doi-asserted-by":"publisher","key":"bibr11-17455057.3.6.719","DOI":"10.1359\/JBMR.040325"},{"unstructured":"First study to demonstrate a similar antifracture efficacy for intermittent and continuous oral administration of ibandronate.","key":"bibr20-17455057.3.6.719"},{"doi-asserted-by":"publisher","key":"bibr12-17455057.3.6.719","DOI":"10.1002\/art.21918"},{"unstructured":"Interesting bridging study showing similar efficacy of oral daily and quarterly intravenous administration of ibandronate on biochemical markers of bone turnover and bone mineral density.","key":"bibr21-17455057.3.6.719"},{"doi-asserted-by":"publisher","key":"bibr13-17455057.3.6.719","DOI":"10.1136\/ard.2005.044958"},{"unstructured":"An interesting bridging study showing similar efficacy of oral daily and oral monthly intravenous administration of ibandronate on biochemical markers of bone turnover and bone mineral density.","key":"bibr22-17455057.3.6.719"},{"doi-asserted-by":"publisher","key":"bibr14-17455057.3.6.719","DOI":"10.2174\/138161205774580750"},{"doi-asserted-by":"publisher","key":"bibr15-17455057.3.6.719","DOI":"10.1056\/NEJMoa044241"},{"doi-asserted-by":"publisher","key":"bibr16-17455057.3.6.719","DOI":"10.1056\/NEJMoa011807"},{"doi-asserted-by":"publisher","key":"bibr17-17455057.3.6.719","DOI":"10.1056\/NEJMoa067312"},{"unstructured":"A major step forward in the management of osteoporosis. The first demonstration that yearly intravenous bisphosphonates can significantly reduce fractures at all skeletal sites.","key":"bibr23-17455057.3.6.719"},{"doi-asserted-by":"publisher","key":"bibr18-17455057.3.6.719","DOI":"10.1007\/s00198-007-0367-3"},{"doi-asserted-by":"publisher","key":"bibr19-17455057.3.6.719","DOI":"10.1016\/j.urology.2005.05.035"}],"container-title":["Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2217\/17455057.3.6.719","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.2217\/17455057.3.6.719","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2217\/17455057.3.6.719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T08:49:48Z","timestamp":1741682988000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.2217\/17455057.3.6.719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["10.2217\/17455057.3.6.719"],"URL":"https:\/\/doi.org\/10.2217\/17455057.3.6.719","relation":{},"ISSN":["1745-5057","1745-5065"],"issn-type":[{"type":"print","value":"1745-5057"},{"type":"electronic","value":"1745-5065"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}